LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

LLY

1,013

-0.56%↓

JNJ

245.32

+0.76%↑

ABBV

223.81

-1.41%↓

NVS

163.17

-1.04%↓

MRK

120.91

+0.23%↑

Search

Cytek Biosciences Inc

Open

SectorHealthcare

4.2 -0.24

Overview

Share price change

24h

Current

Min

4.12

Max

4.25

Key metrics

By Trading Economics

Income

105K

-5.5M

Sales

6.7M

52M

EPS

-0

Profit margin

-10.476

Employees

692

EBITDA

6.4M

-4.2M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+45.52% upside

Dividends

By Dow Jones

Next Earnings

26 Feb 2026

Market Stats

By TradingEconomics

Market Cap

41M

542M

Previous open

4.44

Previous close

4.2

News Sentiment

By Acuity

17%

83%

30 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Cytek Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

18 Feb 2026, 22:31 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 Feb 2026, 22:18 UTC

Earnings

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 Feb 2026, 22:11 UTC

Earnings

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 Feb 2026, 21:52 UTC

Earnings

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 Feb 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 Feb 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 Feb 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 Feb 2026, 23:34 UTC

Market Talk
Earnings

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 Feb 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 Feb 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 Feb 2026, 22:45 UTC

Earnings

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 Feb 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 Feb 2026, 22:37 UTC

Earnings

Nutrien 4Q EPS $1.18 >NTR.T

18 Feb 2026, 22:37 UTC

Earnings

Nutrien 4Q Sales $5.34B >NTR.T

18 Feb 2026, 22:35 UTC

Earnings

Pan American Silver 4Q EPS $1.07 >PAAS

18 Feb 2026, 22:35 UTC

Earnings

Pan American Silver 4Q Rev $1.18B >PAAS

18 Feb 2026, 22:30 UTC

Earnings

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 Feb 2026, 22:29 UTC

Earnings

Kinross Gold 4Q EPS 75c >K.T

18 Feb 2026, 22:22 UTC

Earnings

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 Feb 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 Feb 2026, 22:16 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 Feb 2026, 22:05 UTC

Earnings

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 Feb 2026, 22:03 UTC

Earnings

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 Feb 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 Feb 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Sales $929M >KALU

18 Feb 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 Feb 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Adj EPS 67c >KGC

18 Feb 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Sales $2.02B >KGC

18 Feb 2026, 21:56 UTC

Earnings

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 Feb 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer Comparison

Price change

Cytek Biosciences Inc Forecast

Price Target

By TipRanks

45.52% upside

12 Months Forecast

Average 6.17 USD  45.52%

High 7.5 USD

Low 5 USD

Based on 3 Wall Street analysts offering 12 month price targets forCytek Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

3.7 / 3.8Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

30 / 351 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat